RAE1 and neoplasm: Both monotreatment with Sulanemadlin and the combination treatment, Sulanemadlin + anti-PD-1 immunotherapy led to a significantly higher number of RAE-1 positive cells/mg tumor as well as a significantly higher number of NK cells/mg tumor.